Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL boosted its position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 44.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 735,027 shares of the biopharmaceutical company's stock after purchasing an additional 226,274 shares during the quarter. Tudor Investment Corp ET AL owned about 0.12% of Royalty Pharma worth $18,751,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in RPRX. Barclays PLC lifted its stake in shares of Royalty Pharma by 16.3% in the third quarter. Barclays PLC now owns 308,887 shares of the biopharmaceutical company's stock worth $8,737,000 after buying an additional 43,339 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Royalty Pharma in the 3rd quarter worth approximately $61,000. Franklin Resources Inc. boosted its holdings in shares of Royalty Pharma by 5.0% during the 3rd quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company's stock worth $40,705,000 after purchasing an additional 70,130 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Royalty Pharma by 31.4% in the fourth quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company's stock valued at $63,000 after purchasing an additional 590 shares in the last quarter. Finally, Ridgewood Investments LLC increased its holdings in shares of Royalty Pharma by 40.8% in the fourth quarter. Ridgewood Investments LLC now owns 30,735 shares of the biopharmaceutical company's stock valued at $784,000 after purchasing an additional 8,913 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Trading Up 1.3 %

Shares of RPRX stock traded up $0.41 during trading on Friday, hitting $32.89. 3,138,118 shares of the stock traded hands, compared to its average volume of 3,252,609. Royalty Pharma plc has a 52-week low of $24.05 and a 52-week high of $34.20. The firm has a market capitalization of $18.96 billion, a P/E ratio of 22.68, a price-to-earnings-growth ratio of 2.31 and a beta of 0.50. The firm's fifty day moving average price is $32.46 and its 200-day moving average price is $29.59. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. As a group, research analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be paid a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.68%. The ex-dividend date is Friday, May 16th. Royalty Pharma's dividend payout ratio (DPR) is 60.69%.

Wall Street Analyst Weigh In

Separately, Citigroup restated a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $42.50.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.